provider portal
Wesper Journal
Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.
Continue reading
Zepbound (tirzepatide) has received FDA approval for the treatment of obstructive sleep apnea, now included in Medicare coverage to help manage the condition alongside obesity. This approval marks a shift towards a holistic approach, combining medication with real-time monitoring for...
Continue reading
GLP-1 therapies, such as Zepbound (tirzepatide), address obstructive sleep apnea by aiding weight management, thereby reducing airway pressure and improving respiratory health. Wesper's wearable technology enhances treatment by providing continuous monitoring, allowing for timely adjustments to therapy plans. FDA’s Landmark...
Continue reading
Obstructive sleep apnea (OSA) has been linked to an increased risk of cancer, with individuals suffering from OSA being 1.53 times more likely to receive a cancer diagnosis. The mechanisms involve intermittent hypoxia and inflammation, which can foster an environment...
Continue reading
Obstructive sleep apnea (OSA) significantly increases the risk of developing type 2 diabetes, with over half of individuals with diabetes also experiencing sleep apnea. This complex relationship can exacerbate health outcomes for both conditions, making early screening and integrated management...
Continue reading
